Quick Answer
Nuvectis Pharma, Inc. reported Diluted EPS of $1.32 per share (loss) for fiscal year 2025.
Nuvectis Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.32 | -18.9% |
| 2024 | -$1.11 | +22.4% |
| 2023 | -$1.43 | +5.3% |
| 2022 | -$1.51 | +50.0% |
| 2021 | -$3.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.44 | -83.3% | -46.7% |
| June 30, 2025 | -$0.30 | -15.4% | -11.1% |
| March 31, 2025 | -$0.27 | -8.0% | -12.5% |
| September 30, 2024 | -$0.24 | +35.1% | +7.7% |
| June 30, 2024 | -$0.26 | +31.6% | -4.0% |
| March 31, 2024 | -$0.25 | +7.4% | +32.4% |
| September 30, 2023 | -$0.37 | +11.9% | +2.6% |
| June 30, 2023 | -$0.38 | -35.7% | -40.7% |
- Nuvectis Pharma, Inc. showed a decrease of -18.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s diluted eps has grown by 56.3% (from $3.02 per share (loss) to $1.32 per share (loss)).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: